key: cord-1044610-dyez9gs2 authors: Monfared, Ali; Dashti‐Khavidaki, Simin; Jafari, Ramezan; Jafari, Atefeh; Ramezanzade, Elham; Lebadi, Mohamad‐Kazem; Haghdar‐Saheli, Yalda; Aghajanzadeh, Pegah; Khosravi, Masoud; Movassaghi, Ali; Taghvaye‐Masoumi, Hamidreza; Alavi Foumani, Ali title: Clinical characteristics and outcome of COVID‐19 pneumonia in kidney transplant recipients in Razi hospital, Rasht, Iran date: 2020-08-02 journal: Transpl Infect Dis DOI: 10.1111/tid.13420 sha: d5db709897dc451a55d008e066c1823f99f600a5 doc_id: 1044610 cord_uid: dyez9gs2 BACKGROUND: In late December 2019, a novel coronavirus SARS‐CoV‐2 started to spread around the world in different populations. Its clinical and laboratory characteristics and outcome in kidney transplant recipients are little known. Therefore, we describe 22 kidney transplant recipients with SARS‐CoV‐2–induced pneumonia. METHODS: All kidney transplant recipients who referred to the Razi Hospital of Rasht with a diagnosis of SARS‐CoV‐2 infection from February 20 to 19th of April 2020 have been included in this observational study. RESULTS: We present 22 cases of COVID‐19 in kidney transplant recipients (median age 52 years [interquartile range 40.75‐62.75 years]) and baseline eGFR 60 (mL/min/1.73 m(2)) (44.75‐86.75). Patients complained of cough (72.7%), dyspnea (63.6%), fever (68.2%), and chill (72.7%) with greater prevalence. We decreased the dose of immunosuppression and started stress dose of intravenous hydrocortisone or equivalent oral prednisolone. Each patient received antiviral therapy based on the latest updated version of local protocol at the time of admission. CT scan findings in 90.9% of patients showed bilateral multifocal lesions. Acute kidney injury (AKI) was observed in 12 patients during hospitalization. Six patients died after a median of 12 days from admission (IQR, 1‐21). CONCLUSIONS: In this small observational study, we observed high AKI occurrence and mortality rate in kidney transplant recipients with COVID‐19. infection in kidney transplant recipients is a 52-year-old male from Wuhan who improved 13 days after hospital admission. 5 Our center as a referral hospital for patients with COVID-19 in North Iran admitted kidney transplant recipients. This essay is an observational study of clinical and laboratory characteristics, treatments, and outcome of COVID-19 in 22 kidney transplant recipients admitted in a teaching hospital in North of Iran. All kidney transplant recipients who referred to the Razi Hospital of Rasht with diagnosis of SARS-CoV-2 infection from February 20 to 19th of April 2020 have been included in this observational study. Patients were categorized as probable if they had any acute respiratory and systemic signs and symptoms plus chest CT scan showing lower respiratory tract infection compatible with COVID-19. The diagnosis "confirmed" was used for cases with clinical presentation and chest CT scan compatible with COVID-19 who were laboratoryconfirmed by RT-PCR. 10 On admission, patients were classified based on the severity of infection to mild/moderate/severe/critically ill cases based on case definition by Chen et al. 11 All demographic data and considerable clinical and laboratory information on admission and during hospitalization were gathered. In terms of short-term outcome of kidney function, we followed up patients during 2-8 weeks after discharge. All lung CT scans available to us for this study were reviewed and evaluated by an expert radiologist. Findings including pure groundglass opacity (GGO), crazy-paving, mixed GGO and consolidation, pure consolidation, reversed halo, intralesional vascular enlargement, linear opacities, traction bronchiectasis, mediastinal lymphadenopathies, pleural, and pericardial effusion were documented. There was a CT scan involvement score of zero to five for each lobe, with a total possible score of zero to 25. The total pulmonary involvement score was calculated. 13 The results are expressed as percentage for categorical variables or median (interquartile range; IQR) for continuous variables. The t test, chi-square, and Fisher's exact tests were employed in analyses of variables. P-values of <.05 were considered as statistically significant. The study protocol was approved by the local ethics committee of Guilan University of Medical Sciences. Demographic and baseline clinical characteristics of included patients are shown in Table 1 . Sixty-eight percent of the patients were men, and median age was 52 (IQR, 40.75-62.75). The median duration of hospitalization was 9 days (IQR, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Sixteen patients were discharged from the hospital after a median of 8.5 days from admission (IQR, 5.25-13.5). Four of discharged patients required re-hospitalization because of recurrence of some symptoms. One of these patients finally expired. The total mortality rate was 6/22 (27.27%). Death incidence did not differ between patients in moderate and severe categories of infection (25% vs. 30%, respectively; P = .793). There was no significant difference in demographic characteristics, comorbidities, immunosuppressive regimen, vital signs on admission, blood parameters, type of diagnosis, lesion types and distribution, and score of CT findings between dead and recovered cases (P > .05). While there was no significant difference in symptoms between died and recovered cases, a difference in death between patients who experienced chills symptom with who do not was observed (P = .023). Changes in immunosuppression regimen and drug therapies of kidney transplant recipients on admission and patient outcomes are shown in Table 2 . Mycophenolate was withdrawn in 21 patients. The low dose of glucocorticoids was replaced with a stress dose of intravenous hydrocortisone (60-300 mg/d) or equivalent oral prednisolone ( Table 2 ). As the antiviral regimen used in our protocol has major interaction with calcineurin inhibitor (CNI) metabolism, the dose of tacrolimus or cyclosporine empirically decreased 20%-100% in 17 of the 22 patients. No correlation was found between mortality and variables, including changes in immunosuppression regimen and drug therapies of kidney transplant recipients on admission (P > .05) ( Table 2) . There was no difference in mortality between cases with and without a history of ACEI/ARB use. There was no difference in mortality between cases whose statin was continued or discontinued during hospitalization (P = .083). Among 16 recovered patients, 12 (75%) were using statins before COVID-19 and prescribed to continue during hospitalization. Intravenous immunoglobulin (IVIG) was prescribed to four (18.18%) of the 22 patients, of these patients, one (25%) died (P > .05) (Tables 2. and S1). On admission, serum creatinine was elevated in 40.9% of the patients. The median creatinine level at admission showed a 24.02% increase (IQR, 4.83%-106.56%; range 0%-375%) compared with the baseline, and the peak creatinine level showed 50.9% increment (IQR, 15.39%-131.22%; range 9.68%-511.11%) compared with the baseline. 12 of 22 patients experienced acute kidney injury, and six of them died. Table 3 Note: Data are reported as number and percentages or median (interquartile range) unless otherwise indicated. Unless specified, counts are from the total cohort (N = 22). Abbreviations: BMI, body mass index; BS, blood sugar; BUN, blood urea nitrogen; CK-MB, creatine kinase-MB; CPK, creatine phosphokinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; INR, international normalized ratio; PTT, partial thromboplastin time; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SCr, serum creatinine; WBC, white blood cell. a Prednisolone 5-10 mg/d. median period of 15 days from symptom onset. While we found AKI in near 54% of patients in our study, six of 20 patients (30%) were developed acute kidney injury in another study. 8 Notably, their approaches to immunosuppression regimen management at admission were somewhat different and more homogenous in comparison with the approach of our center. In another preliminary study on seven cases of kidney transplant recipients the mortality rate was 14 %. 7 Recently, a very high early mortality, 28% in 3 weeks, among kidney transplant recipient has been reported 9 that is consistent with our results. In terms of laboratory tests, lymphopenia was observed in 10 of 11 patients with an available lymphocyte count. Other studies showed lymphopenia as a laboratory feature in these patients. 7 Given that the occurrence of AKI in another case series was 57%, 7 it seems that transplant patients are more susceptible for AKI with COVID-19 in comparison with other populations. 19, 20 This study encountered several limitations, including limited sample size and short-term period of follow-up. Another limitation of our study is the heterogeneity in the approach to change or the dose of CNI in patients. Thus, this is an introductory study for designing research with more homogeneity in implementing guideline of immunosuppression dose reduction. Moreover, we missed some laboratory data (eg, lymphocyte count, lactate dehydrogenase, creatine phosphokinase, arterial blood gas, blood concentration of CNIs) because those were not performed in some patients. This defect, along with the small sample size, results in misinterpretation and the inability to draw conclusion. In this study, high AKI occurrence and mortality rate in kidney Returning to the question posed at the beginning of this study, it is now probable to state that kidney transplant recipients may have poor outcomes and prognosis when infected with COVID-19 and require hospitalization and more medical cares. The authors declare no conflict of interest. Note: Data are reported as percentages or median (interquartile range) unless otherwise indicated. Unless specified, counts are from the total cohort (N = 22). Abbreviations: AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; SCr, serum creatinine. a Determined with the CKD Epidemiology Collaboration's CKD-EPI equation b AKI definition: an increase in serum creatinine by 0.3 mg/dL within 48 h or a 50% increase in serum creatinine from baseline within 7 d. When the AKI was detected, the peak serum creatinine level increase of 1.5 to 1.9, 2.0 to 2.9, and more than or equal with 3 times baseline is defined as AKI stage 1, 2, and 3, respectively. Values are numbers (percentages). a Potassium levels below 3.5 mEq/L or above 5 mEq/L defined as hypokalemia or hyperkalemia, respectively. b Sodium levels below 135 mEq/L or above 145 mEq/L defined as hyponatremia or hypernatremia, respectively. c Magnesium levels below 1.8 mg/dL defined as hypomagnesemia. Clinical features of patients infected with 2019 novel coronavirus in Wuhan Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study A novel coronavirus from patients with pneumonia in China Coronavirus disease 2019: implications of emerging infections for transplantation Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? COVID-19 infection in kidney transplant recipients A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia Covid-19 and kidney transplantation Community-acquired respiratory viruses in transplant patients: diversity, impact, unmet clinical needs Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury Novel Coronavirus (COVID-19) pneumonia Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Recommended prophylactic and management strategies for severe acute respiratory syndrome coronavirus 2 infection in transplant recipients Ontological and bioinformatic analysis of anti-coronavirus drugs and their implication for drug repurposing against COVID-19 Why the immune system fails to mount an adaptive immune response to a Covid -19 infection Kidney disease is associated with in-hospital death of patients with COVID-19 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Clinical characteristics and outcome of COVID-19 pneumonia in kidney transplant recipients in Razi hospital